Drug intelligence / Profile preview

XMT-2175

Development stage: Discontinued
Lead developer: Mersana Therapeutics
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

XMT-2175 is an antibody-drug conjugate (ADC) developed by Mersana Therapeutics using their Immunosynthen platform. It is a STING (stimulator of interferon genes, also known as MPYS or STING1 protein) agonist ADC designed to target a tumor-associated antigen in the tumor microenvironment. The drug aims to stimulate the innate immune response against cancer cells by activating the STING pathway, which can promote anti-tumor immunity. As of early 2022, XMT-2175 remains in preclinical development for cancer indications[1][2][3][5].

Other names: XMT 2175XMT2175XMT-2175

Targets

STING (Stimulator of interferon genes protein)

Beyond the preview

Go deeper on XMT-2175.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XMT-2175.

Explore the full profile